NOVARTIS Share Price London S.E.
Stocks
0HKE
CH0012005267
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| Market Cap | 297B 258B 240B 221B 417B 28,365B 424B 2,828B 1,111B 14,129B 1,117B 1,092B 46,810B | P/E 2026 * |
22.2x | P/E 2027 * | 19x |
|---|---|---|---|---|---|
| Enterprise Value | 331B 287B 267B 245B 463B 31,524B 471B 3,143B 1,235B 15,702B 1,241B 1,214B 52,022B | EV / Sales 2026 * |
5.74x | EV / Sales 2027 * | 5.32x |
| Free-Float |
91.66% | Yield 2026 * |
2.8% | Yield 2027 * | 2.92% |
Last Transcript: NOVARTIS
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 31/01/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 15/03/2026 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 15/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 31/12/2014 |
| Director/Board Member | 69 | 31/12/2015 | |
Ton Büchner
BRD | Director/Board Member | 61 | 31/12/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.53% | -3.12% | +51.15% | +150.58% | 1,030B | |
| +0.21% | -1.13% | +53.26% | +46.92% | 617B | |
| -2.51% | -2.33% | +32.56% | +66.35% | 455B | |
| +0.06% | +1.17% | +36.21% | +31.25% | 350B | |
| -0.69% | -0.44% | +9.86% | +14.23% | 265B | |
| -7.37% | -4.31% | -5.69% | -41.99% | 225B | |
| -0.64% | +3.68% | +27.80% | +62.95% | 209B | |
| -0.82% | -0.50% | +13.46% | +69.41% | 163B | |
| +0.40% | -.--% | +5.04% | -30.66% | 142B | |
| Average | -0.89% | +4.58% | +24.85% | +41.00% | 383.99B | |
| Weighted average by Cap. | -0.41% | +4.84% | +35.60% | +69.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.58B 49.95B 46.49B 42.72B 80.72B 5,492B 82.02B 548B 215B 2,736B 216B 212B 9,064B | 61.12B 53.02B 49.35B 45.34B 85.68B 5,830B 87.06B 581B 228B 2,904B 230B 224B 9,621B |
| Net income | 13.78B 11.95B 11.13B 10.22B 19.32B 1,314B 19.63B 131B 51.5B 655B 51.75B 50.61B 2,169B | 15.36B 13.32B 12.4B 11.39B 21.53B 1,465B 21.87B 146B 57.39B 730B 57.67B 56.41B 2,417B |
| Net Debt | 33.11B 28.72B 26.74B 24.57B 46.42B 3,158B 47.16B 315B 124B 1,573B 124B 122B 5,212B | 27.82B 24.13B 22.46B 20.64B 38.99B 2,653B 39.62B 265B 104B 1,322B 104B 102B 4,378B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NOVN Stock
- 0HKE Stock
Select your edition
All financial news and data tailored to specific country editions
